Sudeep Pharma’s Rs 895-crore IPO has seen strong early interest, already oversubscribed on Day 1 with robust demand from retail and NII investors. A rising grey-market premium hints at positive listing expectations. Backed by strong financial growth, advanced manufacturing capabilities, and favourable sector tailwinds, the issue appeals to long-term investors.
